The China Precision Medicine Cloud: A world-leading platform to benefit patients and health

Logo - http://photos.prnewswire.com/prnh/20150915/266982LOGO
Logo - http://photos.prnewswire.com/prnh/20160316/345277LOGO
Logo - http://photos.prnewswire.com/prnh/20160316/345278LOGO

The technology in this platform underpins data infrastructure across China and the largest and most advanced precision medicine projects around the world – from national genome projects to gene discovery,  clinical diagnostics, targeted pharmaceutical development and scientific wellness. It will link scientific excellence and data from across China through a secure nationwide network and governmental, medical, academic and industry collaborations.

A unified cloud that enables both clinical and research genomics in real time, online is the foundation for delivering precision medicine efficiently at national scale. WuXi AppTec and Huawei will follow the guidance of the China Food and Drug Administration (CFDA) and work closely with partner life-science cloud providers to develop the data standards and exchange framework required to deliver the China PMI. WuXi AppTec and WuXi NextCODE solutions already meet US CAP and CLIA standards and include HIPAA-compliant DNAnexus technology delivering the precisionFDA in the United States, so that in implementing guidelines developed by the CFDA the China Precision Medicine Cloud will be well positioned for global compliance and collaboration.    

"It is an honor to have the opportunity to do our part in enabling doctors, scientists, companies and policymakers to develop and implement the most advanced precision medicine across China," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "The China Precision Medicine Cloud aims to harness unique strengths to accelerate innovation. This collaboration is a direct extension of the WuXi commitment to services with high clinical impact, leveraging big data to create the one kind of value that matters: benefit for people and patients."

"We are focused on unlocking the full potential of precision medicine in China," said Hannes Smarason, COO of WuXi NextCODE. "This is a big data challenge, and what we are creating here is the fusion of the largest scale genomics platform and the leading China cloud network. It is a win-win for China Precision Medicine and its impact here and around the world."

About Huawei 
Huawei is a leading global information and communications technology (ICT) solutions provider. Our aim is to enrich life and improve efficiency through a better connected world, acting as a responsible corporate citizen, innovative enabler for the information society, and collaborative contributor to the industry. Driven by customer-centric innovation and open partnerships, Huawei has established an end-to-end ICT solutions portfolio that gives customers competitive advantages in telecom and enterprise networks, devices and cloud computing. Huawei's 170,000 employees worldwide are committed to creating maximum value for telecom operators, enterprises and consumers. Our innovative ICT solutions, products and services are used in more than 170 countries and regions, serving over one-third of the world's population. Founded in 1987, Huawei is a private company fully owned by its employees.

About WuXi AppTec
WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi AppTec's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.

About WuXi NextCODE 
WuXi NextCODE is a genomic information company applying sequence data to deliver better health and precision medicine for people around the world. Our uniquely comprehensive open-access capabilities include CLIA- and CAP-certified sequencing; a novel database architecture that mines and manages more genomes than any other; the world's leading genome interpretation and discovery system, available installed or in the cloud; a pioneering internet of DNA that enables users to query and collaborate using massive genomic datasets online with unrivalled resolution and efficiency; the know-how to apply genomics to optimize drug development; and a growing range of tests and scans to improve rare disease diagnosis, targeted cancer treatment, and wellness. With offices in Shanghai, Cambridge, Massachusetts and Reykjavik, we serve companies and health systems, clinicians and researchers, and people and populations worldwide. WuXi NextCODE is a subsidiary of WuXi AppTec.

Related Links

http://www.wuxinextcode.com